Literature DB >> 9359717

Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors.

Y J Zhang1, C Fracasso, J R Fiore, A Björndal, G Angarano, A Gringeri, E M Fenyö.   

Abstract

Neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates from 17 persons who were long-term disease nonprogressors (LTNPs) and 13 persons who were fast progressors (FPs) was compared. Sera from LTNPs showed higher neutralizing activity both in titer and in host spectrum than did sera from FPs. However, LTNP sera had limited neutralizing activity against HIV-1 subtypes from different geographic areas. Sera collected 6 years earlier from both groups had limited neutralizing activity, indicating that early responses are not predictive for disease progression. LTNPs had very low virus loads, as reflected by only one positive isolation, which was an MT-2-negative phenotype. Virus was isolated from all FPs, and the isolates showed a phenotype switch from MT-2 negative to MT-2 positive. Development of high-titer, broadly cross-reactive neutralizing antibodies is associated with control of virus replication and low virus load in HIV-1-infected LTNPs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359717     DOI: 10.1086/514111

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity.

Authors:  Mohammad M Sajadi; Yongjun Guan; Anthony L DeVico; Michael S Seaman; Mian Hossain; George K Lewis; Robert R Redfield
Journal:  J Acquir Immune Defic Syndr       Date:  2011-05-01       Impact factor: 3.731

Review 3.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.

Authors:  Claudia Pastori; Barbara Weiser; Claudia Barassi; Caterina Uberti-Foppa; Silvia Ghezzi; Renato Longhi; Giliola Calori; Harold Burger; Kimdar Kemal; Guido Poli; Adriano Lazzarin; Lucia Lopalco
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

5.  Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Authors:  Madhumita Mahalanabis; Pushpa Jayaraman; Toshiyuki Miura; Florencia Pereyra; E Michael Chester; Barbra Richardson; Bruce Walker; Nancy L Haigwood
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

6.  Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.

Authors:  Evelien M Bunnik; Linaida Pisas; Ad C van Nuenen; Hanneke Schuitemaker
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

7.  Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.

Authors:  Erin E Verity; Dimitra Zotos; Kim Wilson; Catherine Chatfield; Victoria A Lawson; Dominic E Dwyer; Anthony Cunningham; Jennifer Learmont; Wayne Dyer; John Sullivan; Melissa Churchill; Steven L Wesselingh; Dana Gabuzda; Paul R Gorry; Dale A McPhee
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

8.  Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.

Authors:  Anne Piantadosi; Dana Panteleeff; Catherine A Blish; Jared M Baeten; Walter Jaoko; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.

Authors:  Catherine A Blish; Ozge C Dogan; Nina R Derby; Minh-An Nguyen; Bhavna Chohan; Barbra A Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

10.  Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Maura M Manion; Sijy O'Dell; Adhuna Phogat; Bimal Chakrabarti; Claire W Hallahan; Stephen A Migueles; Jens Wrammert; Rafi Ahmed; Martha Nason; Richard T Wyatt; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.